Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for children
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on children or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on children and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Melatonin (Slenyto) - Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome 1 Published 9 September 2019 1 SMC2168 melatonin 1mg and 5mg prolonged-release tablets (Slenyto®) Flynn Pharma Ltd 9 August 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised (...) as follows: ADVICE: following a full submission melatonin prolonged-release (Slenyto ® ) is not recommended for use within NHSScotland. Indication under review: Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient. Melatonin prolonged-release (Slenyto ® ), compared with placebo, increased total sleep time and sleep onset latency in children aged 2 to 17.5 years with sleep
Management of symptomatic hypermobility in children and young people 1 Guidance for Management of Symptomatic Hypermobility in Children and Young People – A Guide for Professionals managing Children and Young People with this condition This guidance document has been compiled by the Allied Health Professionals Group working within BSPAR Section Council and has been designed to help and support therapists working with children and young people (CYP) presenting with symptomatic hypermobility (...) consensus opinion on the holistic management for CYP with symptomatic hypermobility, using a biopsychosocial model which acknowledges the impact of the condition ? To enable children, young people and their parents/carers to be active participants in the management of the condition ? To optimise the standard of care of CYP with symptomatic hypermobility by empowering them, their carers, and other health professionals through the provision of education, information, support and treatment if required
Digital self-help tools for mental health and wellbeing in children and young peopl Digital self-help tools - Health Technology Wales > Digital self-help tools Digital self-help tools Topic Status Complete Digital self-help tools for mental health and wellbeing in children and young people. Summary Health Technology Wales researchers searched for evidence on the use of digital self-help tools for mental health and wellbeing in children and young people. HTW’s Assessment Group concluded
Common Approach To Children’s Health App CATCH App - Health Technology Wales > CATCH App CATCH App Topic Status Complete Common Approach To Children’s Health App. Summary On behalf of Health Technology Wales, Cedar researchers searched for clinical and health economic evidence on the use of CATCH app by parents and carers of children from conception through pregnancy, birth and up to age of five. HTW’s Assessment Group concluded not to progress this topic further, as there is limited evidence
HbA1c level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study. To evaluate if the lowest target level for glycated haemoglobin (HbA1c) of <6.5% is associated with lower risk for retinopathy and nephropathy than less tight control in children and adults with type 1 diabetes.Population based cohort study.Swedish National Diabetes Registry, 1 January 1998 to 31 December 2017.10 398 children and adults
Immunoglobulin treatment for hospitalised infants and young children with respiratory syncytial virus infection. Millions of children are hospitalised due to respiratory syncytial virus (RSV) infection every year. Treatment is supportive, and current therapies (e.g. inhaled bronchodilators, epinephrine, nebulised hypertonic saline, and corticosteroids) are ineffective or have limited effect. Respiratory syncytial virus immunoglobulin is sometimes used prophylactically to prevent hospital (...) admission from RSV-related illness. It may be considered for the treatment of established severe RSV infection or for treatment in an immunocompromised host, although it is not licenced for this purpose. It is unclear whether immunoglobulins improve outcomes when used as a treatment for established RSV infection in infants and young children admitted to hospital. OBJECTIVES: To assess the effects of immunoglobulins for the treatment of RSV-proven lower respiratory tract infections in children aged up
TNF-α blockers for the treatment of Kawasaki disease in children. Kawasaki disease (KD) is an acute inflammatory vasculitis (inflammation of the blood vessels) that mainly affects children between six months and five years of age. The vasculitis primarily impacts medium-sized blood vessels, especially in the coronary arteries. In most children, intravenous immunoglobulin (IVIG) and aspirin therapy rapidly reduce inflammatory markers, fever, and other clinical symptoms. However, approximately 15 (...) % to 20% of children receiving the initial IVIG infusion show persistent or recurrent fever and are classified as IVIG-resistant. Tumor necrosis factor-alpha (TNF-α) is an inflammatory cytokine that plays an important role in host defence against infections and in immune responses. Several studies have established that blocking TNF-α is critical for obtaining anti-inflammatory effects in children with KD, thus, there is a need to identify benefits and risks of TNF-α blockers for the treatment of KD.To
Association of Gluten Intake During the First 5 Years of Life With Incidence of Celiac Disease Autoimmunity and Celiac Disease Among Children at Increased Risk. High gluten intake during childhood may confer risk of celiac disease.To investigate if the amount of gluten intake is associated with celiac disease autoimmunity and celiac disease in genetically at-risk children.The participants in The Environmental Determinants of Diabetes in the Young (TEDDY), a prospective observational birth (...) cohort study designed to identify environmental triggers of type 1 diabetes and celiac disease, were followed up at 6 clinical centers in Finland, Germany, Sweden, and the United States. Between 2004 and 2010, 8676 newborns carrying HLA antigen genotypes associated with type 1 diabetes and celiac disease were enrolled. Screening for celiac disease with tissue transglutaminase autoantibodies was performed annually in 6757 children from the age of 2 years. Data on gluten intake were available in 6605
Acute Treatment of Migraine in Children and Adolescents 1 Practice guideline update: Acute treatment of migraine in children and adolescents 1 Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the 2 American Academy of Neurology and the American Headache Society 3 4 Maryam Oskoui, MD, MSc, 1 Tamara Pringsheim, MD, 2 Yolanda Holler-Managan, MD, 3 Sonja 5 Potrebic, MD, PhD, 4 Lori Billinghurst MD, MSc, 5 David Gloss, MD, 6 Andrew D. Hershey, MD, 6 PhD, 7 (...) School of Medicine, University of Calgary, Canada 16 4. Neurology Department, Southern California Permanente Medical Group, Kaiser, Los 17 Angeles 18 5. Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, PA 19 6. Department of Neurology, Charleston Area Medical Center, Charleston, WV 20 7. Division of Neurology, Cincinnati Children’s Hospital Medical Center, OH 21 2 8. Department of Neuroscience and Spine, St. Anthony Hospital—Centura Health, 1 Lakewood, CO 2 3 9. University
Global climate change and health in Canadian children Climate change is a reality. Numerous expert authorities warn of the critical need to undertake and adapt environmental efforts to protect human health. Climate change is accelerating, and countries in high latitudes, such as Canada, are experiencing climate change more directly and, for some end points, more dramatically than mid- and low-latitude countries. Children are vulnerable to climate change health effects, and physicians (...) and other health care providers need to be ready to identify, manage, and prevent climate change-related health hazards. This practice point highlights specific, climate change-related threats to the health of children and youth, and provides resources for health care providers. Climate challenges and their health impacts on children are described, based on key Canadian reports and scientifically referenced information. Enhanced awareness of the immediate and longer term health effects of climate change
Improving paediatric medications: A prescription for Canadian children and youth In Canada, policies governing medication approval and reimbursement are based largely on adult standards, and the evaluation of new medicines employs adult return-on-investment benchmarks. Research funding for adult diseases is often prioritized over that for childhood illnesses. Canada lags other countries in implementing regulatory and research-related reforms that take the unique characteristics of children (...) and youth into account. To ensure that children and youth have timely access to safe, effective medications, including child-friendly formulations, the federal government must pursue paediatric-focused reforms that consider their unique health needs throughout the drug life cycle. Regulatory reform must be guided by principles of fairness and equity, always recognizing that children deserve the same standards of drug safety, efficacy, availability, and access as adults. Paediatric experts must drive
Anaesthetic analgesic ear drops to reduce antibiotic consumption in children with acute otitis media: the CEDAR RCT Anaesthetic analgesic ear drops to reduce antibiotic consumption in children with acute otitis media: the CEDAR RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find (...) of Population Medicine, Cardiff University, Cardiff, UK 4 Bristol Randomised Trials Collaboration, Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK 5 Primary Care and Population Sciences, University of Southampton, Southampton, UK 6 Bristol Medical School, Population Health Sciences, University of Bristol, Bristol, UK 7 Bristol Royal Hospital for Children, Bristol, UK 8 Division of Otolaryngology, Department of Surgery, University of British Columbia, Vancouver, BC
Chronic Cough and Gastroesophageal Reflux in Children: CHEST Guideline and Expert Panel Report Whether gastroesophageal reflux (GER) or GER disease (GERD) causes chronic cough in children is controversial. Using the Population, Intervention, Comparison, Outcome (PICO) format, we undertook four systematic reviews. For children with chronic cough (> 4-weeks duration) and without underlying lung disease: (1) who do not have gastrointestinal GER symptoms, should empirical treatment for GERD be used
Diagnostic accuracy of lung ultrasound performed by novice versus advanced sonographers for pneumonia in children: A systematic review and meta-analysis Childhood pneumonia is a leading cause of mortality worldwide. Growing evidence suggests that lung ultrasound (LUS) may be a reliable diagnostic alternative to chest x-ray for childhood pneumonia. However, it is unclear whether sonographer experience affects the diagnostic accuracy of LUS. We summarize the diagnostic accuracy of LUS (...) for pneumonia and compare the performance between novice and advanced sonographers with a systematic review and meta-analysis.We searched PubMed and EMBASE from inception to February 2018 for eligible studies that evaluated the utility of LUS in children suspected of having pneumonia against the reference standard of either imaging results alone or a combination of clinical, laboratory, and imaging results. We reported the study using the Preferred Reporting Items for a Systematic Review and Meta-analysis
Biannual mass azithromycin distributions and malaria parasitemia in pre-school children in Niger: A cluster-randomized, placebo-controlled trial Mass azithromycin distributions have been shown to reduce mortality in preschool children, although the factors mediating this mortality reduction are not clear. This study was performed to determine whether mass distribution of azithromycin, which has modest antimalarial activity, reduces the community burden of malaria.In a cluster-randomized trial (...) conducted from 23 November 2014 until 31 July 2017, 30 rural communities in Niger were randomized to 2 years of biannual mass distributions of either azithromycin (20 mg/kg oral suspension) or placebo to children aged 1 to 59 months. Participants, field staff, and investigators were masked to treatment allocation. The primary malaria outcome was the community prevalence of parasitemia on thick blood smear, assessed in a random sample of children from each community at study visits 12 and 24 months after
Immediate Transfusion in African Children with Uncomplicated Severe Anemia. The World Health Organization recommends not performing transfusions in African children hospitalized for uncomplicated severe anemia (hemoglobin level of 4 to 6 g per deciliter and no signs of clinical severity). However, high mortality and readmission rates suggest that less restrictive transfusion strategies might improve outcomes.In this factorial, open-label, randomized, controlled trial, we assigned Ugandan (...) and Malawian children 2 months to 12 years of age with uncomplicated severe anemia to immediate transfusion with 20 ml or 30 ml of whole-blood equivalent per kilogram of body weight, as determined in a second simultaneous randomization, or no immediate transfusion (control group), in which transfusion with 20 ml of whole-blood equivalent per kilogram was triggered by new signs of clinical severity or a drop in hemoglobin to below 4 g per deciliter. The primary outcome was 28-day mortality. Three other
Transfusion Volume for Children with Severe Anemia in Africa. Severe anemia (hemoglobin level, <6 g per deciliter) is a leading cause of hospital admission and death in children in sub-Saharan Africa. The World Health Organization recommends transfusion of 20 ml of whole-blood equivalent per kilogram of body weight for anemia, regardless of hemoglobin level.In this factorial, open-label trial, we randomly assigned Ugandan and Malawian children 2 months to 12 years of age with a hemoglobin level (...) of less than 6 g per deciliter and severity features (e.g., respiratory distress or reduced consciousness) to receive immediate blood transfusion with 20 ml per kilogram or 30 ml per kilogram. Three other randomized analyses investigated immediate as compared with no immediate transfusion, the administration of postdischarge micronutrients, and postdischarge prophylaxis with trimethoprim-sulfamethoxazole. The primary outcome was 28-day mortality.A total of 3196 eligible children (median age, 37 months